Through this collaboration, we will be able to provide our clients an improved method for producing high quality proteins with increased yields—all while saving them crucial time and money—Tom Foti, Vice President of Aldevron
Menlo Park, Calif. (PRWEB) August 30, 2012
DNA2.0, the leading bioengineering solutions provider, today announced a partnership with Aldevron to improve recombinant protein production in insect cell culture. By pairing DNA2.0‘s GeneGPS™ technology with Aldevron’s protein production experience, the two companies will develop enhanced gene synthesis algorithms for baculovirus protein expression in insect cells.
“Aldevron’s expertise in protein expression and production compliments DNA2.0’s gene design and expression optimization technology,” said Tom Foti, Vice President of Aldevron. “Through this collaboration, we will be able to provide our clients an improved method for producing high quality proteins with increased yields—all while saving them crucial time and money.”
Insect cell expression systems are valued for high expression levels that permit folding, oligomerization and other post-translational modifications in manners that are often identical to those that occur in mammalian cells. By increasing the productivity from insect cell culture, the collaboration between Aldevron and DNA2.0 will further benefit drug discovery research and commercial therapeutic protein production.
“We have successfully optimized expression for a variety of hosts, including bacteria, yeast, fungus, plant and mammalian, and we are excited to team with Aldevron to extend our expertise to baculovirus expression in insect cells,” said Jeremy Minshull, PhD., cofounder and CEO of DNA2.0. “By combining our patented GeneGPS technology—which has been proven to increase protein expression up to 100-fold—with Aldevron’s strength in large scale protein production, I’m confident that we will develop a best-in-class solution for insect cell culture.”
Aldevron is a leader in plasmid DNA purification, protein production and antibody generation. Aldevron manufactures biologics for research, clinical development, diagnostic and commercial applications. Aldevron's capacity, throughput and capabilities support projects in bacterial, insect and mammalian cell systems. By combining innovative technologies with proactive communication and service, Aldevron consistently exceeds client expectations. For more information about Aldevron, visit http://www.aldevron.com.
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.